Beta Bionics
Beta Bionics® is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® Bionic Pancreas System. The iLet Bionic Pancreas is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body's natural ability to maintain tight glycemic control. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation. Beta Bionics operates in Massachusetts and California.
About Beta Bionics
Founded
2015Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$193MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
BiotechnologyLocation
City
ConcordState
MassachusettsCountry
United StatesBeta Bionics
Find your buyer within Beta Bionics